ADMA BIOLOGICS, INC. - COMMON STOCK (ADMA) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2014 to Q4 2025

Type / Class
Equity / COMMON STOCK
Symbol
ADMA on Nasdaq
Shares outstanding
236,833,431
Price per share
$18.24
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
218,118,194
Total reported value
$3,198,429,322
% of total 13F portfolios
0.01%
Share change
+7,420,429
Value change
+$70,759,994
Number of holders
358
Price from insider filings
$18.24
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of ADMA BIOLOGICS, INC. - COMMON STOCK (ADMA) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 15% $726,410,768 35,907,601 BlackRock, Inc. 31 Mar 2025
VANGUARD GROUP INC 8.9% $452,910,758 21,363,715 The Vanguard Group 30 Jun 2025
Invesco Ltd. 5.4% +12% $260,297,468 +$31,774,229 12,866,904 +14% Invesco Ltd. 31 Mar 2025
STATE STREET CORP 5.1% +6% $256,064,306 +$13,519,812 12,078,505 +5.6% STATE STREET CORPORATION 30 Jun 2025

As of 30 Sep 2025, 358 institutional investors reported holding 218,118,194 shares of ADMA BIOLOGICS, INC. - COMMON STOCK (ADMA). This represents 92% of the company’s total 236,833,431 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of ADMA BIOLOGICS, INC. - COMMON STOCK (ADMA) together control 66% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 15% 35,631,714 -2.3% 0.01% $522,360,930
VANGUARD GROUP INC 8.9% 20,974,996 -1.8% 0% $307,493,442
STATE STREET CORP 5.7% 13,561,645 +12% 0.01% $198,813,716
Invesco Ltd. 5.3% 12,505,478 -2.4% 0.03% $183,330,309
Sachem Head Capital Management LP 3.8% 8,960,000 3.7% $131,353,600
GEODE CAPITAL MANAGEMENT, LLC 2.5% 5,813,738 -1.7% 0.01% $85,241,510
Nuveen, LLC 2.4% 5,724,145 +2.9% 0.02% $83,915,966
WESTFIELD CAPITAL MANAGEMENT CO LP 2.2% 5,106,802 0.31% $74,865,717
DIMENSIONAL FUND ADVISORS LP 2% 4,798,274 +0.74% 0.02% $70,343,236
AMERICAN CENTURY COMPANIES INC 2% 4,695,923 +1.8% 0.04% $68,842,245
Thrivent Financial for Lutherans 1.7% 4,141,840 +25% 0.12% $60,719,000
Capital Research Global Investors 1.4% 3,253,913 0.01% $47,702,365
GOLDMAN SACHS GROUP INC 1.2% 2,910,807 +60% 0.01% $42,672,430
RENAISSANCE TECHNOLOGIES LLC 1.2% 2,770,442 -12% 0.05% $40,614,680
OBERWEIS ASSET MANAGEMENT INC/ 1.1% 2,712,040 -14% 1.5% $39,758,506
Caligan Partners LP 1.1% 2,636,609 5.4% $38,652,688
B Group, Inc. 1% 2,412,542 +4.1% 34% $35,367,866
NORTHERN TRUST CORP 1% 2,360,780 -3.4% 0% $34,609,035
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 1% 2,360,765 -5.6% 0.01% $34,608,815
Ranger Investment Management, L.P. 0.99% 2,340,730 -2.1% 2.4% $34,315,102
AWM Investment Company, Inc. 0.93% 2,200,000 0% 3% $32,252,000
PRICE T ROWE ASSOCIATES INC /MD/ 0.91% 2,155,662 +0.77% 0% $31,603,000
Perpetual Ltd 0.89% 2,119,291 -27% 0.39% $31,068,806
CITADEL ADVISORS LLC 0.89% 2,119,162 0.02% $31,066,915
FRANKLIN RESOURCES INC 0.85% 2,002,290 -26% 0.01% $29,353,571

Institutional Holders of ADMA BIOLOGICS, INC. - COMMON STOCK (ADMA) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 2,059,296 $37,344,099 -$50,289,031 $18.24 41
2025 Q3 218,118,194 $3,198,429,322 +$70,759,994 $14.66 358
2025 Q2 211,033,448 $3,839,673,056 +$78,904,673 $18.21 368
2025 Q1 205,274,025 $4,072,971,883 +$76,450,519 $19.84 341
2024 Q4 203,753,698 $3,496,684,473 -$113,984,031 $17.15 316
2024 Q3 207,372,864 $4,143,053,751 +$164,831,793 $19.99 302
2024 Q2 180,864,395 $2,022,116,001 +$85,829,179 $11.18 250
2024 Q1 174,445,611 $1,151,384,319 +$38,701,889 $6.60 212
2023 Q4 340,207 $1,537,735 -$25,570 $4.52 2
2023 Q3 170,334,235 $609,790,066 +$19,868,426 $3.58 186
2023 Q2 164,690,721 $607,649,375 +$1,963,657 $3.69 176
2023 Q1 164,645,526 $544,965,780 +$38,977,196 $3.31 159
2022 Q4 151,948,710 $589,546,624 +$83,695,751 $3.88 157
2022 Q3 129,772,878 $315,351,796 +$25,704,871 $2.43 125
2022 Q2 119,212,509 $236,039,706 +$30,376,968 $1.98 106
2022 Q1 104,891,672 $189,908,374 +$15,213,937 $1.83 101
2021 Q4 96,893,134 $136,610,638 +$70,082,455 $1.41 76
2021 Q3 41,778,741 $47,292,568 -$1,969,628 $1.13 65
2021 Q2 42,401,989 $67,845,517 -$9,376,070 $1.60 81
2021 Q1 48,476,243 $85,314,265 +$4,459,754 $1.76 99
2020 Q4 45,108,342 $87,965,210 -$3,256,517 $1.95 88
2020 Q3 42,589,762 $101,665,108 -$6,943,313 $2.39 88
2020 Q2 48,791,314 $143,044,287 +$1,119,992 $2.93 94
2020 Q1 48,323,756 $139,130,972 +$45,006,201 $2.88 89
2019 Q4 32,447,369 $129,787,396 -$5,590,286 $4.00 71
2019 Q3 37,080,320 $165,001,669 +$9,865,194 $4.45 68
2019 Q2 34,952,413 $135,260,245 +$49,470,429 $3.87 62
2019 Q1 22,292,111 $84,488,596 -$8,215,718 $3.79 53
2018 Q4 24,686,906 $57,964,000 -$3,612,928 $2.39 46
2018 Q3 26,642,017 $165,442,000 +$8,795,325 $6.21 54
2018 Q2 25,528,630 $115,131,787 +$41,329,173 $4.51 50
2018 Q1 16,954,991 $77,991,000 -$211,473 $4.60 34
2017 Q4 17,028,282 $54,659,000 +$27,531,551 $3.21 23
2017 Q3 8,453,450 $26,039,000 -$2,115,749 $3.08 17
2017 Q2 8,911,060 $33,198,000 -$1,175,756 $3.70 19
2017 Q1 9,228,077 $45,033,000 -$611,450 $4.88 17
2016 Q4 9,372,549 $47,987,000 -$550,897 $5.12 17
2016 Q3 9,476,278 $68,659,000 +$188,671 $7.24 18
2016 Q2 9,523,198 $57,439,000 +$6,743,872 $5.95 27
2016 Q1 8,269,534 $66,899,000 -$1,018,593 $8.09 20
2015 Q4 8,422,364 $67,999,000 -$508,962 $8.07 24
2015 Q3 7,049,589 $58,936,000 +$163,030 $8.36 22
2015 Q2 3,421,139 $31,680,000 +$720,808 $9.26 22
2015 Q1 3,341,529 $32,743,000 +$9,198,956 $9.80 17
2014 Q4 2,367,783 $26,447,585 +$14,273,682 $11.17 11
2014 Q3 776,863 $8,002,000 +$1,130,613 $10.30 1
2014 Q2 667,099 $6,504,000 +$6,504,015 $9.75 1